Key result
Transitioning to a turkey herpesvirus vector vaccine followed by a tissue culture-origin vaccine resolved severe infectious laryngotracheitis outbreaks and eliminated the virus within 1 year.
Why the study?
Does a transition to a turkey herpesvirus vector vaccine followed by a tissue culture-origin vaccine resolve infectious laryngotracheitis outbreaks in commercial layer pullets?
Case Report
No
Does a transition to a turkey herpesvirus vector vaccine followed by a tissue culture-origin vaccine resolve infectious laryngotracheitis outbreaks in commercial layer pullets?
Transitioning from a CEO modified live vaccine to a turkey herpesvirus vector vaccine and tissue culture-origin vaccine successfully resolved a severe vaccine-origin ILT outbreak in a commercial pullet farm.
May inform ILT control in pullets; leaves open confirmation in controlled trials before wider use.
A multiage commercial layer pullet operation with a history of chicken embryo-origin (CEO) modified live infectious laryngotracheitis (ILT) virus vaccination suffered severe ILT outbreaks in 2017. The initial sequencing revealed that the circulating virus was of vaccine origin. Changes to the timing and dosage of CEO ILT vaccine failed to control the outbreak. The clinical resolution of the outbreak occurred with the transition to a turkey herpesvirus vector vaccine given in-hatchery, followed by a tissue culture-origin vaccine given on the farm. The circulating ILT viruses were monitored periodically by next-generation sequencing. This site became free of ILT virus within 1 yr after implementing the new vaccination program.
No takes yet. Share an insight, caveat, or question.
Carrier et al. (2021) conducted a case report in Infectious laryngotracheitis (ILT). Turkey herpesvirus vector vaccine given in-hatchery, followed by a tissue culture-origin vaccine given on the farm vs. Chicken embryo-origin (CEO) modified live ILT virus vaccination was evaluated on Clinical resolution of the outbreak and freedom from ILT virus. Transitioning to a turkey herpesvirus vector vaccine followed by a tissue culture-origin vaccine resolved severe infectious laryngotracheitis outbreaks and eliminated the virus within 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: